Novo Nordisk Cuts GLP-1 Drug Prices Up to 50%; WADA Monitors Use, Brazil Reports 65 Deaths
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.